These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 25281027)
41. Expression and significance of CD44, CD47 and c-met in ovarian clear cell carcinoma. Wang H; Tan M; Zhang S; Li X; Gao J; Zhang D; Hao Y; Gao S; Liu J; Lin B Int J Mol Sci; 2015 Feb; 16(2):3391-404. PubMed ID: 25658794 [TBL] [Abstract][Full Text] [Related]
42. Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. Ma Y; Zhang P; Gao Y; Fan H; Zhang M; Wu J Int J Clin Exp Pathol; 2015; 8(11):14875-84. PubMed ID: 26823817 [TBL] [Abstract][Full Text] [Related]
43. Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin. Cheng JC; Auersperg N; Leung PC Oncogene; 2011 Mar; 30(9):1020-31. PubMed ID: 20972462 [TBL] [Abstract][Full Text] [Related]
44. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma. Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934 [TBL] [Abstract][Full Text] [Related]
45. Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. Rahman MT; Nakayama K; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Nakayama N; Otsuki Y; Nakayama S; Miyazaki K Br J Cancer; 2012 Jul; 107(2):300-7. PubMed ID: 22653145 [TBL] [Abstract][Full Text] [Related]
46. Dysregulated PI3K/Akt/PTEN pathway is a marker of a short disease-free survival in node-negative breast carcinoma. Capodanno A; Camerini A; Orlandini C; Baldini E; Resta ML; Bevilacqua G; Collecchi P Hum Pathol; 2009 Oct; 40(10):1408-17. PubMed ID: 19428048 [TBL] [Abstract][Full Text] [Related]
47. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis. Ayhan A; Kuhn E; Wu RC; Ogawa H; Bahadirli-Talbott A; Mao TL; Sugimura H; Shih IM; Wang TL Mod Pathol; 2017 Feb; 30(2):297-303. PubMed ID: 27767100 [TBL] [Abstract][Full Text] [Related]
48. PI3K/AKT pathway regulates E-cadherin and Desmoglein 2 in aggressive prostate cancer. Barber AG; Castillo-Martin M; Bonal DM; Jia AJ; Rybicki BA; Christiano AM; Cordon-Cardo C Cancer Med; 2015 Aug; 4(8):1258-71. PubMed ID: 26033689 [TBL] [Abstract][Full Text] [Related]
49. Correlation between PTEN expression and PI3K/Akt signal pathway in endometrial carcinoma. Gao Q; Ye F; Xia X; Xing H; Lu Y; Zhou J; Ma D J Huazhong Univ Sci Technolog Med Sci; 2009 Feb; 29(1):59-63. PubMed ID: 19224164 [TBL] [Abstract][Full Text] [Related]
50. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352 [TBL] [Abstract][Full Text] [Related]
51. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women. Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324 [TBL] [Abstract][Full Text] [Related]
52. Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. Okamoto A; Sehouli J; Yanaihara N; Hirata Y; Braicu I; Kim BG; Takakura S; Saito M; Yanagida S; Takenaka M; Yamaguchi N; Morikawa A; Tanabe H; Yamada K; Yoshihara K; Enomoto T; Itamochi H; Kigawa J; Matsumura N; Konishi I; Aida S; Aoki Y; Ishii N; Ochiai K; Akiyama T; Urashima M PLoS One; 2015; 10(2):e0116977. PubMed ID: 25658832 [TBL] [Abstract][Full Text] [Related]
53. Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma. De Marco C; Rinaldo N; Bruni P; Malzoni C; Zullo F; Fabiani F; Losito S; Scrima M; Marino FZ; Franco R; Quintiero A; Agosti V; Viglietto G PLoS One; 2013; 8(2):e55362. PubMed ID: 23408974 [TBL] [Abstract][Full Text] [Related]
54. Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad. Quinlan KG; Verger A; Yaswen P; Crossley M Biochim Biophys Acta; 2007 Jun; 1775(2):333-40. PubMed ID: 17572303 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665 [TBL] [Abstract][Full Text] [Related]
56. Prognosis and gene expression profiling of 20q13-amplified breast cancers. Ginestier C; Cervera N; Finetti P; Esteyries S; Esterni B; Adélaïde J; Xerri L; Viens P; Jacquemier J; Charafe-Jauffret E; Chaffanet M; Birnbaum D; Bertucci F Clin Cancer Res; 2006 Aug; 12(15):4533-44. PubMed ID: 16899599 [TBL] [Abstract][Full Text] [Related]
57. IGF-1 mediates PTEN suppression and enhances cell invasion and proliferation via activation of the IGF-1/PI3K/Akt signaling pathway in pancreatic cancer cells. Ma J; Sawai H; Matsuo Y; Ochi N; Yasuda A; Takahashi H; Wakasugi T; Funahashi H; Sato M; Takeyama H J Surg Res; 2010 May; 160(1):90-101. PubMed ID: 19560785 [TBL] [Abstract][Full Text] [Related]
59. Clinical analysis and literature review of a case of ovarian clear cell carcinoma with PIK3CA gene mutation: A case report. Farah AM; Gu S; Jia Y Medicine (Baltimore); 2022 Sep; 101(37):e30666. PubMed ID: 36123851 [TBL] [Abstract][Full Text] [Related]
60. [Effects of PTEN over-expression on phosphatidyl inositol 3-kinase/protein kinase B signal pathway in ovarian epithelial cancer cells]. Zhai YN; Xu LL; Shen Y; Xia H; Shen YF Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):682-5. PubMed ID: 21092549 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]